CAR-T: from bench to bedside
In current immunotherapy, a promising direction is therapy using chimeric antigen receptor T cells (CAR-T). Among malignant hematological diseases, even at advanced stages and resistant/recurrent forms, the use of CAR-T demonstrates high efficiency. The observed clinical success in patients with hem...
Saved in:
| Main Authors: | M. О. Popova, V. V. Markelov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2024-09-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/951 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Study of the suppression of a tumor growth expressing a carcinoembryonic antigen with a new high-tech drug carplasmin (CAR-T therapy) in Balb/c nude mice
by: V. K. Bozhenko, et al.
Published: (2023-04-01) -
The use of T-cells with chimeric antigen receptor (CAR-T) in combination with chemotherapy and radiotherapy for the treatment of solid tumors
by: M. R. Khaliulin, et al.
Published: (2024-04-01) -
Expanding the Horizons of CAR-T Cell Therapy: A Review of Therapeutic Targets Across Diverse Diseases
by: Alejandrina Hernández-López, et al.
Published: (2025-01-01) -
Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematology
by: Alina Ershova, et al.
Published: (2025-07-01) -
Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
by: Eugenio Galli, et al.
Published: (2021-10-01)